MX354103B - Composicion inmunogenica. - Google Patents
Composicion inmunogenica.Info
- Publication number
- MX354103B MX354103B MX2014009250A MX2014009250A MX354103B MX 354103 B MX354103 B MX 354103B MX 2014009250 A MX2014009250 A MX 2014009250A MX 2014009250 A MX2014009250 A MX 2014009250A MX 354103 B MX354103 B MX 354103B
- Authority
- MX
- Mexico
- Prior art keywords
- saccharide
- protein
- capsular
- polysaccharide
- conjugates
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 2
- 150000004676 glycans Chemical class 0.000 abstract 5
- 229920001282 polysaccharide Polymers 0.000 abstract 5
- 239000005017 polysaccharide Substances 0.000 abstract 5
- 150000001720 carbohydrates Chemical class 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 102000014914 Carrier Proteins Human genes 0.000 abstract 2
- 108010078791 Carrier Proteins Proteins 0.000 abstract 2
- 241000588650 Neisseria meningitidis Species 0.000 abstract 2
- 230000021615 conjugation Effects 0.000 abstract 2
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a conjugados de proteína de polisacárido inmunogénicos que comprenden polisacáridos capsulares a partir del serogrupo X de N. Meningitidis y métodos para la preparación de los mismos. La presente invención se refiere a conjugados de proteína de sacárido X-portadora de N. Meningitidis preparados por medio de una reacción de conjugación. En consecuencia, la presente invención se refiere a una composición de conjugado de proteína de polisacárido meningocóccica multivalente que comprende un sacárido capsular a partir de los serogrupos X y por lo menos un sacárido capsular a partir de A, C, W135 e Y en donde, i) polisacáridos A C W135 X son dimensionados mecánicamente en tanto que el polisacárido Y es dimensionado químicamente, ii) todos los sacáridos son conjugados para proteína portadora a través de un enlazador con una química de conjugación por cíanilación iii) todas las relaciones de sacárido a proteína en los conjugados finales están entre 0.2-0.6 y iv) se utilizan por lo menos dos proteínas portadoras diferentes son seleccionadas a partir del grupo que consta de TT, DTyCRM197.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN281MU2012 | 2012-01-30 | ||
| PCT/IB2013/050739 WO2013114268A1 (en) | 2012-01-30 | 2013-01-29 | Immunogenic composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014009250A MX2014009250A (es) | 2015-03-19 |
| MX354103B true MX354103B (es) | 2018-02-13 |
Family
ID=54259032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014009250A MX354103B (es) | 2012-01-30 | 2013-01-29 | Composicion inmunogenica. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9198977B2 (es) |
| EP (1) | EP2809349B1 (es) |
| JP (1) | JP6042455B2 (es) |
| KR (1) | KR101897317B1 (es) |
| CN (1) | CN104302315B (es) |
| BR (1) | BR112014018815B1 (es) |
| CA (1) | CA2863178C (es) |
| DK (1) | DK2809349T3 (es) |
| ES (1) | ES2707294T3 (es) |
| HU (1) | HUE040914T4 (es) |
| MX (1) | MX354103B (es) |
| PT (1) | PT2809349T (es) |
| RU (1) | RU2634405C2 (es) |
| SG (1) | SG11201404447WA (es) |
| SI (1) | SI2809349T1 (es) |
| TR (1) | TR201900778T4 (es) |
| WO (1) | WO2013114268A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130122810A (ko) | 2005-06-27 | 2013-11-08 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 제조 방법 |
| MX364644B (es) * | 2012-11-21 | 2019-05-03 | Serum Inst India Ltd | Produccion de altos rendimientos de polisacaridos bacteriales. |
| MX365726B (es) * | 2013-08-24 | 2019-06-11 | Bharat Biotech Int Ltd | Vacuna bacteriana y metodos para la fabricacion de la misma. |
| EP2921856B1 (en) | 2014-03-18 | 2016-09-14 | Serum Institute Of India Private Limited | A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines |
| PE20180460A1 (es) * | 2015-06-08 | 2018-03-06 | Serum Inst Of India Private Ltd | Metodos para mejorar la adsorcion de conjugados de polisacarido-proteina y una formulacion de vacuna multivalente obtenida con los mismos |
| AU2016290233A1 (en) * | 2015-07-04 | 2018-01-25 | Bharat Biotech International Limited | Polysaccharide vaccine formulations and processes for industrial production of bacterial polysaccharides |
| MX2018010920A (es) * | 2016-03-15 | 2019-03-06 | Msd Wellcome Trust Hilleman Laboratories Pvt Ltd | Nuevos conjugados de polisacarido-proteina, y procedimiento para obtener los mismos. |
| CN106110316A (zh) * | 2016-06-27 | 2016-11-16 | 北京智飞绿竹生物制药有限公司 | 一种肺炎球菌结合物组合疫苗的制备方法 |
| LT3506935T (lt) | 2016-09-02 | 2024-04-25 | Sanofi Pasteur, Inc. | Vakcina nuo neisseria meningitidis |
| CN106397537B (zh) * | 2016-10-13 | 2020-01-07 | 李红臣 | 一种高效快速的多糖蛋白结合疫苗纯化分析方法 |
| CA3062399A1 (en) | 2017-05-05 | 2018-11-08 | Serum Institute Of India Private Limited | Method for removal of impurities from bacterial capsular polysaccharide based preparations |
| BR112019027182A2 (pt) * | 2017-06-27 | 2020-06-30 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | nova composição de vacina conjugada de proteína - polissacarídeo multivalente e formulação da mesma |
| WO2019145981A1 (en) * | 2018-01-29 | 2019-08-01 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Novel meningococcal vaccine composition and process thereof |
| WO2019198096A1 (en) * | 2018-04-11 | 2019-10-17 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Tetravalent meningococcal vaccine composition and process to prepare thereof |
| JOP20200214A1 (ar) | 2019-09-03 | 2021-03-03 | Serum Institute Of India Pvt Ltd | تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها |
| MX2022003682A (es) | 2019-09-27 | 2022-04-25 | Pfizer | Composiciones de neisseria meningitidis y metodos de las mismas. |
| US12053515B2 (en) | 2020-08-10 | 2024-08-06 | Inventprise, Inc. | Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F |
| CN118078981A (zh) * | 2024-04-26 | 2024-05-28 | 成都康华生物制品股份有限公司 | 一种基于双蛋白载体的五价脑膜炎球菌多糖结合疫苗的制备方法及其产品 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2763244B1 (fr) * | 1997-05-14 | 2003-08-01 | Pasteur Merieux Serums Vacc | Composition vaccinale multivalente a porteur mixte |
| HU227893B1 (en) * | 2000-06-29 | 2012-05-29 | Glaxosmithkline Biolog Sa | Vaccine compositions |
| GB0115176D0 (en) * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| GB0130215D0 (en) * | 2001-12-18 | 2002-02-06 | Glaxosmithkline Biolog Sa | Vaccine |
| EP1961426B1 (en) * | 2003-10-02 | 2011-04-27 | Novartis Vaccines and Diagnostics S.r.l. | Combined meningitis vaccines |
| GB0513069D0 (en) * | 2005-06-27 | 2005-08-03 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| KR20130122810A (ko) * | 2005-06-27 | 2013-11-08 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 제조 방법 |
| BRPI0615420A2 (pt) * | 2005-09-01 | 2011-05-17 | Novartis Vaccines & Diagnostic | vacinação múltipla que inclui meningococo do sorogrupo c |
| DK2384765T3 (en) * | 2005-12-22 | 2017-01-09 | Glaxosmithkline Biologicals Sa | Vaccine against Streptococcus pneumoniae. |
| GB0703369D0 (en) * | 2007-02-21 | 2007-03-28 | Health Prot Agency | Compositions Comprising Capsular Polysaccharides and Their Use as Vaccines |
| SG181750A1 (en) * | 2009-12-17 | 2012-07-30 | Fina Biosolutions Llc | Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines |
| ES2820898T3 (es) * | 2012-05-22 | 2021-04-22 | Glaxosmithkline Biologicals Sa | Conjugado del serogrupo X de meningococos |
-
2013
- 2013-01-29 SI SI201331329T patent/SI2809349T1/sl unknown
- 2013-01-29 PT PT13743463T patent/PT2809349T/pt unknown
- 2013-01-29 MX MX2014009250A patent/MX354103B/es active IP Right Grant
- 2013-01-29 SG SG11201404447WA patent/SG11201404447WA/en unknown
- 2013-01-29 ES ES13743463T patent/ES2707294T3/es active Active
- 2013-01-29 WO PCT/IB2013/050739 patent/WO2013114268A1/en not_active Ceased
- 2013-01-29 CA CA2863178A patent/CA2863178C/en active Active
- 2013-01-29 DK DK13743463.5T patent/DK2809349T3/da active
- 2013-01-29 TR TR2019/00778T patent/TR201900778T4/tr unknown
- 2013-01-29 KR KR1020147024348A patent/KR101897317B1/ko active Active
- 2013-01-29 US US14/375,385 patent/US9198977B2/en active Active
- 2013-01-29 HU HUE13743463A patent/HUE040914T4/hu unknown
- 2013-01-29 EP EP13743463.5A patent/EP2809349B1/en active Active
- 2013-01-29 BR BR112014018815-7A patent/BR112014018815B1/pt active IP Right Grant
- 2013-01-29 JP JP2014555364A patent/JP6042455B2/ja active Active
- 2013-01-29 CN CN201380017781.9A patent/CN104302315B/zh active Active
- 2013-01-29 RU RU2014134288A patent/RU2634405C2/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014009250A (es) | 2015-03-19 |
| CN104302315A (zh) | 2015-01-21 |
| US20140377302A1 (en) | 2014-12-25 |
| US9198977B2 (en) | 2015-12-01 |
| SG11201404447WA (en) | 2014-08-28 |
| DK2809349T3 (da) | 2019-02-18 |
| ES2707294T3 (es) | 2019-04-03 |
| EP2809349A1 (en) | 2014-12-10 |
| CN104302315B (zh) | 2018-02-06 |
| JP2015509111A (ja) | 2015-03-26 |
| RU2634405C2 (ru) | 2017-10-26 |
| WO2013114268A1 (en) | 2013-08-08 |
| BR112014018815B1 (pt) | 2022-07-12 |
| EP2809349B1 (en) | 2018-12-19 |
| PT2809349T (pt) | 2019-02-01 |
| RU2014134288A (ru) | 2016-03-20 |
| CA2863178C (en) | 2021-04-06 |
| KR101897317B1 (ko) | 2018-09-11 |
| BR112014018815A2 (es) | 2017-06-20 |
| TR201900778T4 (tr) | 2019-02-21 |
| JP6042455B2 (ja) | 2016-12-14 |
| EP2809349A4 (en) | 2015-08-26 |
| KR20140123553A (ko) | 2014-10-22 |
| BR112014018815A8 (pt) | 2017-07-11 |
| HUE040914T4 (hu) | 2019-05-28 |
| SI2809349T1 (sl) | 2019-03-29 |
| CA2863178A1 (en) | 2013-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014009250A (es) | Composicion inmunogenica. | |
| MY148110A (en) | Immunogenic composition | |
| PH12018501517A1 (en) | Neisseria meningitidis compositions and methods thereof | |
| PH12021551159A1 (en) | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions | |
| NZ595291A (en) | Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates | |
| JP2014218516A5 (es) | ||
| MX2020002558A (es) | Procesos para la formulacion de polisacaridos neumococicos para la conjugacion a una proteina transportadora. | |
| MX2009013949A (es) | Vacuna que comprende conjugados de polisacárido capsular de streptococcus pneumoniae. | |
| TR201900418T4 (tr) | Pnömokok polisakkarit konjugat aşısı. | |
| IN2014DN09791A (es) | ||
| GB201101665D0 (en) | Immunogenic compositions | |
| MX2021014710A (es) | Un conjugado inmunogenico de polisacarido de neumococo del serotipo 35b- proteina y proceso de conjugacion para preparar el mismo. | |
| WO2006067632A3 (en) | Saccharide conjugate vaccines | |
| GB2455447A (en) | Method of producing meningococcal meningitis vaccine for neisseria meningitidis serotypes A, C,Y and W-135 | |
| JP2015509111A5 (es) | ||
| MX2014014067A (es) | Conjugado de serogrupo x de meningococo. | |
| HRP20240433T1 (hr) | Cjepivo protiv neisseria meningitidis | |
| BRPI0915517B8 (pt) | método para a produção de um conjugado de vi, conjugado, e, composição farmacêutica | |
| WO2015052684A3 (en) | Polysaccharide-protein conjugates with enhanced immunogenicity and rapid high yielding process of preparation thereof | |
| MX382165B (es) | Una vacuna conjugada contra n. meningitidis para usarse en la prevención o tratamiento de enfermedades por n. meningitidis. | |
| FI2968427T3 (fi) | Konjugaatti sienisoluseinämän polysakkarideihin kohdentuvien vasta-aineiden indusoimiseksi | |
| MX2007007790A (es) | Conjugados y vacuna de proteina con polisacarido derivado meningococcal multivalente. | |
| UA95075C2 (uk) | Імуногенна композиція | |
| EA201990131A1 (ru) | Поливалентная пневмококковая полисахаридно-белковая конъюгатная композиция | |
| IN2013DE03047A (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |